Paper Details

  1. Home
  2. Paper Details

Breast development in a 7 year old girl with CF treated with ivacaftor: An indication for personalized dosing?

Author: BeekmanJeffrey M, BerkersGitte, HeijermanHarry Gm, JeyaratnamJoshena, van der EntCornelis K, van der MeerRenske

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

CFTR modulators have revolutionized cystic fibrosis treatment, but long-term side effects are still under investigation. This report describes a 7-year-old girl with CF who developed breast development as a rare dose-dependent side effect of ivacaftor treatment. The study also found that higher plasma concentrations of ivacaftor did not correlate with clinical effect, suggesting that some patients may benefit from lower doses.
Paper Details　
Original Abstract of the Article :
Substantial progress has been made in the treatment of Cystic fibrosis due to introduction of CFTR modulators. However, little is known about the long term side effects of treatment with these drugs. We here present a 7 year old girl with CF who presented with breast development as a rare dose depen...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jcf.2021.06.001

データ提供：米国国立医学図書館（NLM）

Breast Development in a 7-Year-Old Girl with Cystic Fibrosis: A Case for Personalized Dosing

The development of [CFTR modulators] has revolutionized the treatment of [Cystic fibrosis (CF)], but the long-term effects of these medications remain largely unknown. This case report describes a [7-year-old girl with CF] who developed [breast development] as a rare side effect of [ivacaftor] treatment. The authors highlight the need for personalized dosing strategies to optimize treatment effectiveness and minimize potential adverse effects. The findings suggest that [ivacaftor] plasma concentrations may vary significantly among patients, emphasizing the importance of individualizing treatment plans to ensure optimal outcomes.

Personalized Dosing: Tailoring Treatment to Individual Needs

This research emphasizes the importance of [personalized dosing] in [CF] treatment. The case report highlights the potential for variability in [ivacaftor] plasma concentrations among patients, underscoring the need for individualized treatment approaches. This could involve adjusting medication dosages based on factors such as [body weight] and [body surface area] to optimize therapeutic effects and minimize potential side effects. The findings suggest that a more personalized approach to [CF] management could lead to improved patient outcomes.

Optimizing CFTR Modulator Therapy

This study calls for a more nuanced approach to [CFTR modulator] therapy, recognizing the importance of individual patient characteristics and the potential for variability in drug response. The authors suggest that a more individualized dosing strategy could optimize treatment outcomes, minimize potential adverse effects, and ultimately improve the quality of life for [CF] patients.

Dr. Camel's Conclusion

This case report provides a valuable reminder of the importance of personalized medicine, particularly in the context of [Cystic fibrosis (CF)] treatment. The findings highlight the need for careful monitoring and adjustment of [ivacaftor] dosages to optimize treatment effectiveness and minimize potential adverse effects, ultimately leading to better patient outcomes.

Date :
  1. Date Completed 2022-02-07
  2. Date Revised 2022-02-07
Further Info :

Pubmed ID

34175243

DOI: Digital Object Identifier

10.1016/j.jcf.2021.06.001

Related Literature

Article Analysis
・Side Effects of ivacaftor
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.